Literature DB >> 8414499

MHC class I expression in HPV 16 positive cervical carcinomas is post-transcriptionally controlled and independent from c-myc overexpression.

F V Cromme1, P J Snijders, A J van den Brule, P Kenemans, C J Meijer, J M Walboomers.   

Abstract

Squamous cell carcinomas of the uterine cervix (n = 23) were selected for the presence of human papillomavirus type 16 (HPV 16) using the polymerase chain reaction (PCR). Localization of transcripts coding for the E7 protein was demonstrated in neoplastic cells with RNA in situ hybridization. Consecutive tissue sections were investigated for expression of the major histocompatibility complex class I (MHC-I) and c-myc using immunohistochemical double staining procedures, since a role has been suggested for the c-myc protein in MHC-I down-regulation and c-myc overexpression has been described in cervical carcinomas. Reduced expression of class I heavy chains was observed in neoplastic cells from 18 out of 23 carcinomas (78%). Varying levels of c-myc overexpression were observed in 12 carcinomas (52%), from which four showed positive MHC-I expression in c-myc overexpressing cells. In the remaining eight c-myc overexpressing carcinomas MHC-I down-regulation was observed. Additional RNA in situ hybridization with class I heavy chain locus-specific RNA-probes revealed presence of class I mRNAs in those neoplastic cells that show negative staining for MHC-I protein. These data strongly indicate that MHC-I down-regulation in cervical carcinomas involves post-transcriptional mechanisms, not directly related to E7 transcription and overexpression of c-myc.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8414499

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  Altered expression of TAP-1 and major histocompatibility complex class I in laryngeal papillomatosis: correlation of TAP-1 with disease.

Authors:  A Vambutas; V R Bonagura; B M Steinberg
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

2.  Human papillomavirus type 16 (HPV 16) E7 and major histocompatibility complex (MHC) class I and II expression in human keratinocytes in culture.

Authors:  A Hoos; C D'Incan; L Gissmann; A Altmann; F Momburg; I Nindl; W Osen; B H Schönning; I Jochmus
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

Review 3.  The biological properties of E6 and E7 oncoproteins from human papillomaviruses.

Authors:  Raffaella Ghittoni; Rosita Accardi; Uzma Hasan; Tarik Gheit; Bakary Sylla; Massimo Tommasino
Journal:  Virus Genes       Date:  2009-10-17       Impact factor: 2.332

4.  Genetic variants in TAP are associated with high-grade cervical neoplasia.

Authors:  Mark H Einstein; Suzanne Leanza; Lydia G Chiu; Nicolas F Schlecht; Gary L Goldberg; Bettie M Steinberg; Robert D Burk
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

Review 5.  Selective mechanisms utilized by persistent and oncogenic viruses to interfere with antigen processing and presentation.

Authors:  R Ehrlich
Journal:  Immunol Res       Date:  1995       Impact factor: 2.829

6.  The E5 protein of the human papillomavirus type 16 down-regulates HLA-I surface expression in calnexin-expressing but not in calnexin-deficient cells.

Authors:  Myriam Gruener; Ignacio G Bravo; Frank Momburg; Angel Alonso; Pascal Tomakidi
Journal:  Virol J       Date:  2007-10-30       Impact factor: 4.099

7.  Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours.

Authors:  F V Cromme; P F van Bommel; J M Walboomers; M P Gallee; P L Stern; P Kenemans; T J Helmerhorst; M J Stukart; C J Meijer
Journal:  Br J Cancer       Date:  1994-06       Impact factor: 7.640

8.  Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas.

Authors:  F V Cromme; J Airey; M T Heemels; H L Ploegh; P J Keating; P L Stern; C J Meijer; J M Walboomers
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

9.  Nuclear proto-oncogene products transactivate the human papillomavirus type 16 promoter.

Authors:  W Nürnberg; M Artuc; G Vorbrueggen; F Kalkbrenner; K Moelling; B M Czarnetzki; D Schadendorf
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.